Expression of LKB1 gene in bone marrow of patients with acute non-lymphocytic leukemia and its clinical significance / 中国输血杂志

ABSTRACT

【Objective】 To investigate the expression level of liver kinase B1 (LKB1) gene in bone marrow of patients with acute non-lymphoblastic leukemia (AML) and its correlation with prognosis. 【Methods】 A total of 90 AML patients from May 2015 to January 2017 were selected as study subjects, and 30 cases of bone marrow specimens from non-malignant hematologic diseases were selected as control group. The expression of LKB1 mRNA in bone marrow was detected by real-time fluorescent quantitative PCR (qRT-PCR). The expression of LKB1 protein was detected by Western blot. The correlation between LKB1 mRNA and prognosis of AML was analyzed by Kaplan-Meier survival analysis. 【Results】 The mutation rate of LKB1 gene, the mRNA and LKB1 protein expression in bone marrow of AML patients was lower than those of control group (χ2=13.274, t=34.134, t=45.235, P<0.05). The mutation rate of LKB1 gene and the mRNA expression from high to low order is M1(81%, 17/21)>M5(78.6%, 11/14)>M6(75%, 3/4)>M2(42.4%, 14/33)>M4(41.7%, 5/12)>M3(35.3%, 6/17). Thefollow-up survival rate of patients with AML in the LKB1 high amplification group was higher than that of patients with LKB1 low amplification(χ2=8.039, P<0.05) The median survival time of the LKB1 high amplification group was higher than that of the LKB1low amplification group (27.3 months vs 19.8 months) (χ2=5.552, P<0.05). The incidence of post-chemotherapy infection, post-chemotherapy recurrence and extramedullary infiltration in the LKB1 high amplification group was lower than that in patients with LKB1 low amplification (P>0.05). 【Conclusion】 The expression level of LKB1 gene in patients with AML is low, moreover the more low expression level of LKB1 gene were, the more severe ill condition and more poor prognosis.